JNJ-63723283

JNJ-63723283 Uses, Dosage, Side Effects, Food Interaction and all others data.

JNJ-63723283 is under investigation in clinical trial NCT03547037 (A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers).

Trade Name	JNJ-63723283
Generic	Cetrelimab
Cetrelimab Other Names	Cetrelimab, JNJ-63723283
Type
Groups	Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Innovators Monograph

You find simplified version here JNJ-63723283